Pliant Therapeutics
David Phillips is the current Scientific Advisor at Pliant Therapeutics. Prior to this, they served as the Vice President of Quality at Kiniksa Pharmaceuticals from February 2019 to March 2020. In this role, they were responsible for overseeing GMP, GLP, GCP, GDP, and GVP quality for the company. David also established the overall strategic long-term vision for quality at Kiniksa, including the hiring and growth plans, identification of specific talent roles needed, establishment of quality agreements and relationships with key external partners, and inspection roadmaps.
From July 2013 to February 2019, David served as the Vice President of Quality at Shire. In this role, they were responsible for leading a team of quality professionals and ensuring that all products met regulatory requirements. David also oversaw the implementation of quality systems and procedures across the company.
Prior to their time at Shire, David was the Director at Lonza Biologics Singapore from April 2007 to June 2013. In this role, they oversaw the production of biologic drugs and ensured that they met all quality standards. David also managed tech transfer for Celltrion and VaxGen.
David Phillips has a Bachelor's degree in Biochemistry from North Carolina State University and an MBA in New Product Development from the same school.
This person is not in the org chart
This person is not in any offices
Pliant Therapeutics
Pliant is advancing drug development programs targeting a range of fibrotic diseases, with a focus on fibrotic tissue-specific inhibition of integrins and the TGF-β pathway.